[go: up one dir, main page]

AU2003276220A1 - Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a) - Google Patents

Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a)

Info

Publication number
AU2003276220A1
AU2003276220A1 AU2003276220A AU2003276220A AU2003276220A1 AU 2003276220 A1 AU2003276220 A1 AU 2003276220A1 AU 2003276220 A AU2003276220 A AU 2003276220A AU 2003276220 A AU2003276220 A AU 2003276220A AU 2003276220 A1 AU2003276220 A1 AU 2003276220A1
Authority
AU
Australia
Prior art keywords
pde2a
therapeutics
diagnostics
diseases associated
human phosphodiesterase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003276220A
Inventor
Ulf Bruggemeier
Stefan Golz
Holger Summer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of AU2003276220A1 publication Critical patent/AU2003276220A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/916Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003276220A 2002-11-13 2003-10-31 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a) Abandoned AU2003276220A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02025505.5 2002-11-13
EP02025505 2002-11-13
PCT/EP2003/012124 WO2004044234A1 (en) 2002-11-13 2003-10-31 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a)

Publications (1)

Publication Number Publication Date
AU2003276220A1 true AU2003276220A1 (en) 2004-06-03

Family

ID=32309338

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003276220A Abandoned AU2003276220A1 (en) 2002-11-13 2003-10-31 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a)

Country Status (3)

Country Link
EP (1) EP1597386A1 (en)
AU (1) AU2003276220A1 (en)
WO (1) WO2004044234A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
WO2006018088A1 (en) * 2004-08-19 2006-02-23 Switch Biotech Ag Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders
DK1759700T3 (en) * 2004-08-19 2009-10-12 Switch Biotech Llc Use of a PDE5 inhibitor for the treatment and prevention of hypopigmentation disorders
DE102006048693A1 (en) * 2006-10-14 2008-04-17 Bayer Healthcare Ag Inhibition of PDE2A
JP6157455B2 (en) 2012-04-25 2017-07-05 武田薬品工業株式会社 Nitrogen-containing heterocyclic compounds
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
WO2014142255A1 (en) 2013-03-14 2014-09-18 武田薬品工業株式会社 Heterocyclic compound
JP6411342B2 (en) 2013-07-03 2018-10-24 武田薬品工業株式会社 Amide compounds
JP6427491B2 (en) 2013-07-03 2018-11-21 武田薬品工業株式会社 Heterocyclic compounds
PL3597649T3 (en) 2014-04-23 2022-04-04 Dart Neuroscience Llc Compositions containing substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors
WO2016073424A1 (en) 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted 5-methyl-[1, 2, 4] triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors
AU2017388054B2 (en) 2016-12-28 2022-03-24 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL132366A0 (en) * 1998-10-15 2001-03-19 Cell Pathways Inc Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds
US6376225B1 (en) * 2001-01-05 2002-04-23 Pe Corporation (Ny) Isolated human phosphodiesterase proteins, nucleic acid molecules encoding human phosphodiesterase proteins, and uses thereof
US6465494B1 (en) * 2001-08-24 2002-10-15 Cell Pathways, Inc. Methods for treatment of cystic fibrosis

Also Published As

Publication number Publication date
EP1597386A1 (en) 2005-11-23
WO2004044234A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
AU2003251471A1 (en) Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5)
AU2003269193A1 (en) Imaging and measurement system
SI1603915T1 (en) SUBSTITUTED 8 -PYRIDINYL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE AND 8 -PYRIMIDIN YL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES
AU2003276220A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a)
AU2003301894A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
AU2003229735A1 (en) Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
AU2003276136A1 (en) Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
AU2003283303A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
AU2003274083A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 10a (pde10a)
AU2003205627A1 (en) Diagnostics and therapeutics for diseases associated with gpr72
AU2003267380A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a (pde11a)
AU2003279361A1 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7B (PDE7b)
AU2003283427A1 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 9a1 (pde9a1)
AU2003294728A1 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 9a2 (PDE9a2)
AU2003252075A1 (en) Human immunosuppressive protein
AU2003289894A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 9a4 (pde9a4)
AU2003288158A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4c (pde4c)
AU2003279323A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b)
AU2003288171A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 9a3 (pde9a3)
AU2003282087A1 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A1 (PDE7a1)
AU2003276187A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8a (pde8a)
AU2003283302A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a1 (pde11a1)
AU2003206749A1 (en) Diagnostics and therapeutics for diseases associated with the gpr65 receptor
AU2003279322A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a3 (pde11a3)
AU2003274082A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4a (pde4a)

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase